

Table S1: PD-1 pathway inhibitor regarding the timing of immunotherapy and radiotherapy

	Number	%
SRT before IT	18	21.4
Nivolumab	10	55.6
Pembrolizumab	7	38.9
Durvalumab	0	0
Atezolizumab	1	5.5
Concurrent SRT and IT	46	54.8
Nivolumab	27	58.7
Pembrolizumab	15	32.6
Durvalumab	3	6.5
Atezolizumab	1	2.2
SRT after IT	20	23.8
Nivolumab	6	30
Pembrolizumab	7	35
Durvalumab	7	35
Atezolizumab	0	0

Table S2: Multivariate analysis for Regional Progression-Free Interval

MULTIVARIATE		R-PFI			
Factors		n	HR	CI	Pvalue
Sex	Female	37	1		0.113
	Male	47	0.62	[0.34 ; 1.12]	
Age at SRT	< 60 y	26	1		0.163
	≥ 60 y	58	0.62	[0.32 ; 1.2]	
Treatment	Conc SRT - IT	46	1		0.114
	SRT before IT	18	1.57	[0.77 ; 3.2]	
	SRT after IT	20	2.33	[1.04 ; 5.24]	
IT line	1	28	1		0.006
	≥2	23	1.78	[0.86 ; 3.7]	
	Consolidation ("Durvalumab group")	10	0.35	[0.1 ; 1.17]	

HR, Hazard Ratio; CI, confidence interval; SRT, stereotactic radiotherapy; IT, immunotherapy; y, years

